

# Markus Cornberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6770105/markus-cornberg-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

282  
papers

14,345  
citations

57  
h-index

113  
g-index

347  
ext. papers

17,759  
ext. citations

6.7  
avg, IF

7.08  
L-index

#	Paper	IF	Citations
282	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
281	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3285	4.9	
280	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 863039	8.4	0
279	Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 838132	8.4	0
278	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 396-415	18.8	11
277	The curing regimens of HCV: A SWOT analysis.. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 13596535211072672	1.6	0
276	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	0
275	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 733-744	6.1	2
274	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. <i>Gut</i> , <b>2021</b> , 70, 1734-1745	19.2	5
273	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 32, 223-229	2.2	2
272	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
271	Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 415-423	2.2	1
270	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , <b>2021</b> ,	19.2	3
269	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , <b>2021</b> , 41, 1815-1823	7.9	0
268	EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 944-951	13.4	61
267	Experimental Drugs for the Treatment of Hepatitis D. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 461-468	3	6
266	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. <i>Liver International</i> , <b>2021</b> , 41, 1518-1522	7.9	1

265	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , <b>2021</b> , 41, 2046-2058	7.9	0
264	Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 667253	6	2
263	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab325	1	0
262	Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1206-1218	3.4	4
261	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 74, 72-82	11.2	6
260	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , <b>2021</b> , 34, 275-287	5.4	3
259	Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , <b>2021</b> , 27, 887-899	4.5	1
258	Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-Registry. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1660-1664	3.4	1
257	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 229-231	13.4	1
256	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 46-60.e8	6.9	15
255	A transient early HBV-DNA increase during PEG-IFN $\alpha$ therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 410-419	3.4	1
254	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFN $\alpha$ -based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. <i>Liver International</i> , <b>2021</b> , 41, 295-299	7.9	8
253	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 801-810	13.4	12
252	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1053-1063	13.4	23
251	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. <i>Hepatology Communications</i> , <b>2021</b> , 5, 97-111	6	3
250	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 195-198.e2	6.9	5
249	Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2021</b> , 12, 99-117	7.9	4
248	Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	6

247 Management of Patients with Acute Hepatitis C **2021**, 141-152

246	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , <b>2021</b> , 12, 1152	17.4	37
245	COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. <i>Immunity</i> , <b>2021</b> , 54, 340-354.e6	32.3	87
244	Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 486-496	5.3	0
243	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 296	3	1
242	Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 487-489	13.4	5
241	Impact of the COVID-19 pandemic on patients with liver cirrhosis-the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 954-960	1.6	0
240	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , <b>2021</b> , 142, 104932	14.5	1
239	Towards eradication of HBV: Treatment approaches and status of clinical trials. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 60, 232-240	5.1	1
238	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
237	Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. <i>Liver International</i> , <b>2020</b> , 40, 1507	7.9	
236	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 696-699	13.4	13
235	PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	2
234	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. <i>Cells</i> , <b>2020</b> , 9,	7.9	3
233	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235199	3.7	1
232	HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , <b>2020</b> , 4, 983-997	6	2
231	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , <b>2020</b> , 129, 104525	14.5	1
230	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1112-1121	13.4	22

229	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa040	1	11
228	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , <b>2020</b> , 2, 100113	10.3	280
227	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 841-846	1.6	1
226	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , <b>2020</b> , 40, 324-332	7.9	2
225	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 194-195	6.1	5
224	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 539-557	13.4	88
223	Global timing of hepatitis C virus elimination in high-income countries. <i>Liver International</i> , <b>2020</b> , 40, 522-529	7.9	77
222	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , <b>2020</b> , 57, 102885	8.8	65
221	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , <b>2020</b> , 72, 1378-1393	11.2	13
220	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3349-3358	5.1	7
219	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1359-1368	3.4	14
218	TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. <i>Gut</i> , <b>2020</b> ,	19.2	15
217	UEG framework for the development of high-quality clinical guidelines. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 851-864	5.3	3
216	Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. <i>Frontiers in Public Health</i> , <b>2020</b> , 8, 424	6	8
215	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , <b>2020</b> , 2, 100169	10.3	68
214	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. <i>Liver International</i> , <b>2020</b> , 40, 539-548	7.9	11
213	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230893	3.7	1
212	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2076	8.4	5

211	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , <b>2019</b> , 9, 14118	4.9	5
210	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 673-684	13.4	10
209	Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 67-74	2.2	3
208	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. <i>Cells</i> , <b>2019</b> , 8,	7.9	2
207	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 301-312	13.4	34
206	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 397-408	13.4	163
205	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	4
204	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , <b>2019</b> , 156, 1820-1833	13.3	23
203	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 275-286	25.5	57
202	Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 696-706	6.1	21
201	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1033-1041	2.4	8
200	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0220666	3.7	6
199	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 889-899	13.4	31
198	Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 512-521	1	2
197	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , <b>2019</b> , 71, 1070	11.2	23
196	Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 230-240	2.2	4
195	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , <b>2019</b> , 8, 41-65.1		17
194	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1008-1015	13.4	40



193	Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 224-230	3.4	8
192	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 466-475	3.4	4
191	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , <b>2018</b> , 93, 150-153	7.5	26
190	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1656-1666	7	31
189	Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. <i>Liver International</i> , <b>2018</b> , 38, 1602-1613	7.9	21
188	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 920-929	3.4	2
187	Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. <i>HIV Medicine</i> , <b>2018</b> , 19, 299-307	2.7	30
186	Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2018</b> , 15, 195-196	24.2	11
185	Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 961-971	3.8	2
184	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , <b>2018</b> , 154, 976-988.e4	13.3	102
183	Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , <b>2018</b> , 38, 2317-2328	7.9	6
182	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 383-403	18.8	702
181	Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , <b>2018</b> , 38, 266-277	7.9	9
180	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , <b>2018</b> , 38, 842-850	7.9	41
179	Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. <i>Liver International</i> , <b>2018</b> , 38, 834-841	7.9	5
178	A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 547-555	6.1	21
177	Human T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 510	8.4	17
176	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 584-593	13.4	55

175	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , <b>2018</b> , 35, 843-857	4.7	10
174	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , <b>2018</b> , 9, 2275	17.4	48
173	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1480-1484	7	22
172	Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 516-525	6.1	42
171	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 712-721	2.2	3
170	Differential escape pathways from the dominant CD8 T cell epitope in HBV core18 Δ7 depend on the HLA class I genotype. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, E2-E89	1.6	
169	Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, E2-E89	1.6	
168	Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , <b>2018</b> , 56, e288-e289	1.6	
167	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 851-853	13.4	3
166	Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfecting patients: insights from the German Hepatitis C-Registry. <i>HIV Clinical Trials</i> , <b>2018</b> , 19, 225-234		
165	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1188-1198	5.3	14
164	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , <b>2018</b> , 9, 189	4.2	11
163	New viral biomarkers for Hepatitis B: Are we able to change practice?. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1226-1235	3.4	14
162	Reply to Liaw. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1853-1854	7	
161	Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 688-700	6.1	33
160	Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 67-72	7.9	3
159	What is new on HBsAg and other diagnostic markers in HBV infection?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2017</b> , 31, 281-289	2.5	19
158	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 939-945	2.2	20



157	Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S101	13.4	8
156	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 193-194	13.4	
155	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, 848-856	1.6	11
154	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1541-1543	5.1	1
153	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 609-618	4.7	9
152	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 918-924	13.4	146
151	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 680-686	13.4	29
150	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , <b>2017</b> , 17, 215-222	25.5	78
149	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 139-149	7	19
148	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , <b>2017</b> , 65, 414-425	11.2	52
147	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 398-411	13.4	191
146	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. <i>Liver International</i> , <b>2017</b> , 37, 205-211	7.9	27
145	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 525	8.4	19
144	Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1210	8.4	26
143	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 187-92 <sup>2.2</sup>		2
142	Management of HBV and HBV/HDV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , <b>2016</b> , 32, 86-94	2.4	11
141	The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , <b>2016</b> , 36, 473-6	7.9	2
140	Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype. <i>Virology Journal</i> , <b>2016</b> , 13, 67	6.1	5

139	Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23 Suppl 1, 1-12	3.4	21
138	Clinical Virology: Diagnosis and Virologic Monitoring. <i>Molecular and Translational Medicine</i> , <b>2016</b> , 205-216.4		
137	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1481-1489.e5	6.9	36
136	Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , <b>2016</b> , 16, 41-48	7.5	17
135	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1228-1234	11.6	19
134	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 561-7	11.6	72
133	ImPortance of IP-10 in hepatitis B. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 93-6	1.6	12
132	Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 mono-infection: Final results of the German HepNet Acute HCV IV Study. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6	1404
131	Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes an HEV peptide and an apoptotic epitope. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2016</b> , 54, 1343-1404	1.6	
130	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1821-1830.e6	6.9	46
129	Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , <b>2016</b> , 46, 2204-10	6.1	102
128	Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 305-15	3.4	19
127	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 473-82	13.4	55
126	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1492-1497	7	78
125	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , <b>2016</b> , 65, 1733-43	39.2	101
124	Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1965-1974	7	79
123	Hepatitis C: individualised medicine versus one pill fits all. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 86-87	18.8	4
122	Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 546-7	6.1	4

121	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 606.e1-10	9.5	75
120	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , <b>2015</b> , 89, 8304-17	6.6	28
119	P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S524-S525	13.4	5
118	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-Induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 710.e1-9	9.5	35
117	Effects of HDV infection and pegylated interferon treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , <b>2015</b> , 64, 469-82	19.2	39
116	Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis. <i>Journal of Virology</i> , <b>2015</b> , 89, 10786-801	6.6	17
115	New kids on the block--step by step to an ideal HCV therapy. <i>Lancet, The</i> , <b>2015</b> , 385, 1050-2	4.0	9
114	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 31-40	13.4	44
113	Comprehensive phenotyping of regulatory T cells after liver transplantation. <i>Liver Transplantation</i> , <b>2015</b> , 21, 381-95	4.5	4
112	Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 889-901	6.1	84
111	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , <b>2015</b> , 35, 2275-84	7.9	
110	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 270	8.4	22
109	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128069	3.7	4
108	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145622	3.7	2
107	When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2015</b> , 9, 260-2	4.9	8
106	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. <i>Journal of Leukocyte Biology</i> , <b>2015</b> , 98, 283-94	6.5	9
105	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , <b>2015</b> , 35, 1845-52	7.9	19
104	Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 85-92	6.1	26

103	Development and evaluation of a baseline-event-anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, e154-63	3.4	35
102	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 34-59	3.4	271
101	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 5-33	3.4	182
100	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , <b>2014</b> , 34, 1207-15	7.9	5
99	Compromised function of natural killer cells in acute and chronic viral hepatitis. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1362-73	7	80
98	Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. <i>Hepatology</i> , <b>2014</b> , 60, 1112-3	11.2	21
97	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 769-79	3.4	19
96	Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. <i>PLoS ONE</i> , <b>2014</b> , 9, e108751	3.7	13
95	Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection. <i>Clinical Investigation</i> , <b>2014</b> , 4, 361-371		1
94	How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. <i>Viral Immunology</i> , <b>2014</b> , 27, 7-13	1.7	5
93	HBsAg seroclearance with NUCs: rare but important. <i>Gut</i> , <b>2014</b> , 63, 1208-9	19.2	19
92	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , <b>2014</b> , 60, 87-97	11.2	159
91	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21 Suppl 1, 60-89	3.4	140
90	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 836-45	2.2	19
89	PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. <i>PLoS ONE</i> , <b>2014</b> , 9, e94512	3.7	15
88	Anti-HDV IgM as a marker of disease activity in hepatitis delta. <i>PLoS ONE</i> , <b>2014</b> , 9, e101002	3.7	31
87	The role of HBsAg levels in the current management of chronic HBV infection. <i>Annals of Gastroenterology</i> , <b>2014</b> , 27, 105-112	2.2	34
86	The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1365-72	6.1	30

85	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. <i>Current Hepatitis Reports</i> , <b>2013</b> , 12, 261-268		
84	Extrahepatic Manifestations of Hepatitis C Virus Infection <b>2013</b> , 295-309		1
83	Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. <i>Liver International</i> , <b>2013</b> , 33, 722-6	7.9	126
82	Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 378-9	25.5	26
81	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 497-506	25.5	73
80	Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 475	8.4	64
79	Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. <i>PLoS ONE</i> , <b>2013</b> , 8, e55285	3.7	82
78	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , <b>2012</b> , 55, 695-708	11.2	126
77	NK cells in hepatitis C: role in disease susceptibility and therapy. <i>Digestive Diseases</i> , <b>2012</b> , 30 Suppl 1, 48-54	3.2	16
76	EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 167-85	13.4	2480
75	Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 27-31	7.9	27
74	Interferon $\alpha$ stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 1351-62	7	37
73	Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. <i>PLoS Pathogens</i> , <b>2012</b> , 8, e1002633	7.6	26
72	Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. <i>Viral Immunology</i> , <b>2012</b> , 25, 442-7	1.7	12
71	Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e43143	3.7	33
70	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , <b>2011</b> , 50, 292-6	14.5	67
69	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1121-31	13.4	237
68	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 554-563	13.4	43

67	Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 915-24	1.6	67
66	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , <b>2011</b> , 31 Suppl 2, 30-60	7.9	293
65	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. <i>Liver International</i> , <b>2011</b> , 31, 1395-405	7.9	34
64	Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002045	7.6	94
63	Natural killer cells act as rheostats modulating antiviral T cells. <i>Nature</i> , <b>2011</b> , 481, 394-8	50.4	424
62	CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. <i>Journal of Immunology</i> , <b>2010</b> , 184, 2825-38	5.3	61
61	Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2010</b> , 48, 258-63	1.6	13
60	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 514-22	13.4	311
59	Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. <i>Gastroenterology</i> , <b>2010</b> , 138, 1885-97	13.3	154
58	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , <b>2010</b> , 16, 74-82	4.5	149
57	Treatment of chronic hepatitis B. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2010</b> , 56, 451-65	1.6	10
56	Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity. <i>Journal of Immunology</i> , <b>2009</b> , 183, 6554-60	5.3	12
55	The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2009</b> , 47, 531-40	1.6	24
54	Adenosine and IFN- $\alpha$ synergistically increase IFN- $\gamma$ production of human NK cells. <i>Journal of Leukocyte Biology</i> , <b>2009</b> , 85, 452-61	6.5	14
53	Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , <b>2009</b> , 342, 33-48	2.5	24
52	Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 2079-88	19.7	20
51	Clearance of chronic HCV infection during acute delta hepatitis. <i>Infection</i> , <b>2009</b> , 37, 159-62	5.8	25
50	Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. <i>Vaccine</i> , <b>2009</b> , 27, 3099-108	4.1	4



49	Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. <i>Blood</i> , <b>2009</b> , 113, 4440-8	2.2	14
48	State-of-the-Art Lecture: Treatment of hepatitis C <b>2009</b> , 105-119		
47	The German guideline for the management of hepatitis B virus infection: short version. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15 Suppl 1, 1-21	3.4	22
46	Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. <i>Vaccine</i> , <b>2008</b> , 26, 3818-26	4.1	36
45	Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 860-5	5.1	35
44	Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2008</b> , 46, 880-2	1.6	5
43	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 200-11	3.4	19
42	Prevalence of HBV genotypes in Central and Eastern Europe. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 1707-11	1.7	42
41	Spontaneous clearance of chronic hepatitis C after liver transplantation: are hepatitis C virus-specific T cell responses the clue?. <i>Liver Transplantation</i> , <b>2008</b> , 14, 1225-7	4.5	13
40	Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. <i>Journal of Virology</i> , <b>2007</b> , 81, 934-44	6.6	30
39	Making sense of muscle fatigue and liver lesions. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2007</b> , 45, 609-11	1.6	2
38	Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2007</b> , 45, 1281-328	1.6	49
37	Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. <i>Vaccine</i> , <b>2007</b> , 25, 6793-806	4.1	35
36	Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. <i>Virology Journal</i> , <b>2007</b> , 4, 58	6.1	31
35	Immune Responses in Acute and Chronic Hepatitis C <b>2007</b> , 193-208		
34	Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 303-16	1.6	5
33	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 303-316	1.6	17
32	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. <i>Hepatology</i> , <b>2006</b> , 43, 250-6	11.2	195

31	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <i>Hepatology</i> , <b>2006</b> , 43, 1311-6	11.2	35
30	Reply:. <i>Hepatology</i> , <b>2006</b> , 44, 511-512	11.2	1
29	Future trends in hepatitis C therapy. <i>Future Virology</i> , <b>2006</b> , 1, 99-107	2.4	3
28	Present and future therapy for hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , <b>2006</b> , 4, 781-93	5.5	11
27	Treating viral hepatitis C: efficacy, side effects, and complications. <i>Gut</i> , <b>2006</b> , 55, 1350-9	19.2	474
26	Treatment of acute hepatitis C-how to explain the differences?. <i>Gastroenterology</i> , <b>2006</b> , 131, 682-3; author reply 683-4	13.3	4
25	Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 291-301	13.4	63
24	Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 770-8	13.4	44
23	Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. <i>Immunological Reviews</i> , <b>2006</b> , 211, 164-81	11.3	147
22	Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1443-56	15.9	112
21	The privacy of T cell memory to viruses. <i>Current Topics in Microbiology and Immunology</i> , <b>2006</b> , 311, 117-53	3.3	29
20	New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 144-150	3.1	2
19	Private specificities of CD8 T cell responses control patterns of heterologous immunity. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 523-33	16.6	111
18	Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 3602-12	15.9	129
17	Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. <i>Helicobacter</i> , <b>2004</b> , 9, 371-86	4.9	19
16	Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , <b>2004</b> , 40, 98-107	17.2	62
15	CD8 memory T cells: cross-reactivity and heterologous immunity. <i>Seminars in Immunology</i> , <b>2004</b> , 16, 335-47	4.7	94
14	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. <i>Current Hepatitis Reports</i> , <b>2003</b> , 2, 24-31		1

13	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , <b>2002</b> , 4, 23-30	5	77
12	Polyethylene glycol-interferon: current status in hepatitis C virus therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2002</b> , 17 Suppl 3, S344-50	4	12
11	Fate of goblet cells in experimental colitis. <i>Digestive Diseases and Sciences</i> , <b>2002</b> , 47, 2286-97	4	22
10	Significance of the caspase family in Helicobacter pylori induced gastric epithelial apoptosis. <i>Helicobacter</i> , <b>2002</b> , 7, 367-77	4.9	26
9	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 843-7	13.4	25
8	Treatment of acute hepatitis C with interferon alfa-2b. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1452-7	37.2	634
7	Current and future treatment of hepatitis C. <i>Indian Journal of Gastroenterology</i> , <b>2001</b> , 20 Suppl 1, C47-51	1.9	7
6	Hepatitis C: therapeutic perspectives. <i>Forum: Trends in Experimental and Clinical Medicine</i> , <b>2001</b> , 11, 154-62		5
5	Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. <i>Inflammation Research</i> , <b>2000</b> , 49, 162-9	7.2	114
4	Expression of leptin and leptin receptor isoforms in the human stomach. <i>Gut</i> , <b>2000</b> , 47, 481-6	19.2	130
3	Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , <b>1999</b> , 276, G164-72	5.1	27
2	Variation of human mucin gene expression in gastric cancer cell lines and gastric mucous cell primary cultures. <i>European Journal of Cell Biology</i> , <b>1999</b> , 78, 832-41	6.1	14
1	Morphological and molecular characterization of human gastric mucous cells in long-term primary culture. <i>Pflügers Archiv European Journal of Physiology</i> , <b>1998</b> , 436, 871-81	4.6	9